Vivek Subbiah: Welcoming Deepak Bhamidipati to Sarah Cannon Research Institute Early Phase Drug Development Unit
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA), shared a post on LinkedIn:
“Delighted to welcome Dr. Deepak Bhamidipati to our Sarah Cannon Research Institute Early Phase Drug Development Unit in Nashville!
Recipient of the prestigious American Society of Clinical Oncology (ASCO) YIA and Merit Awards, he will be a fantastic addition to our team SCRI Oncology Partners The US Oncology Network Nashville, TN
He recently graduated from MD Anderson Cancer Center my alma mater & one of the best oncology fellowship training programs in the nation. It’s an exciting time to enter clinical trials research & oncology drug development.
Join me in welcoming Dr. Bhamidipati to SCRI!”
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer. He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023